English
Français
Our advanced gene therapy technology capitalizes on our differentiated knowledge of direct-to-brain administration of AAV vectors, allowing us to precisely target the causes of disease.
Extraordinary progress in developing therapies for CNS diseases with lead programs in neurodegenerative lysosomal storage disorders.
Our team is committed to developing pioneering therapies that will transform the lives of children affected by these devastating diseases.
Our team is committed to fulfilling gene therapy’s potential by developing pioneering therapies that will transform the lives of children affected by these devastating diseases.
News, press releases, and more.
Cash and cash equivalents of €7.7 million[1] as of 30 June 2022 Paris, France —…
Paris, France —11 July 2022 at 06:00 pm — Lysogene (FR0013233475 – LYS) —…
• Positive biomarker data confirmed in additional subjects and at additional timepoints • Stable or…
Paris, France —27 June 2022 at 8:00 am CET — Lysogene (FR0013233475 – LYS),…
Paris, France —03 June 2022 at 6:00 pm CET — Lysogene (FR0013233475 – LYS),…
• Promising efficacy data in young patients with persistent increase or stabilization in 3 main…
Cash and cash equivalents of €10.7 million[1] as of 31 March 2022 Paris, France —…
Paris, France — 21 April 2022 at 08:00 am CEST — Lysogene (FR0013233475 – LYS),…
Paris, France — 20 April 2022 at 08:00 am — Lysogene (FR0013233475 – LYS), a…
Lysogene exercises its option after a conclusive research collaboration period Paris, France — 12 April 2022…
Valuable information designed to provide knowledge and insights to patients, families, and caregivers.
Mucopolysaccharidosis type IIIA (MPS IIIA), or Sanfilippo syndrome type A, is a rare neurodegenerative lysosomal storage disorder characterized by intractable behavioral problems and developmental regression that typically appears in infancy or early childhood.
GM1 gangliosidosis, or Landing disease, is a rare inherited neurodegenerative lysosomal storage disorder characterized by severe cognitive and motor developmental delays.
Fragile X syndrome (FXS) is the most common inherited cause of autism spectrum disorder and affects approximately 1 in 4,000 to 5,000 boys and 1 in 8,000 girls.
Neuronopathic Gaucher and Parkinson’s disease are both associated with mutations in the GBA1 gene and cause neurological symptoms.
The EURORDIS Company Award for Innovation recognizes Lysogene as a pioneering gene therapy company which has established itself among major players driving European-led innovation, in just over ten years.
